Guggenheim raised the firm’s price target on Merck (MRK) to $122 from $104 and keeps a Buy rating on the shares. The firm’s target raise is largely driven by inclusion of probability-adjusted revenues for Winrevair in the population investigated in the Phase 2 CADENCE trial, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck & Co. Closes $7 Billion Notes Offering
- Halozyme wins preliminary injunction against Merck’s Keytruda SC in Germany
- Merck Animal Health announces conditional FDA approval of Exzolt Cattle-CA1
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports